Sangamo Therapeutics Inc (SGMO)
0.5209
+0.01
(+2.12%)
USD |
NASDAQ |
Apr 23, 16:00
0.5191
0.00 (0.00%)
After-Hours: 20:00
Sangamo Therapeutics Research and Development Expense (Quarterly): 50.71M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 50.71M |
| September 30, 2023 | 57.09M |
| June 30, 2023 | 63.05M |
| March 31, 2023 | 63.22M |
| December 31, 2022 | 66.18M |
| September 30, 2022 | 65.12M |
| June 30, 2022 | 60.02M |
| March 31, 2022 | 58.58M |
| December 31, 2021 | 51.80M |
| September 30, 2021 | 62.50M |
| June 30, 2021 | 60.09M |
| March 31, 2021 | 56.43M |
| December 31, 2020 | 52.36M |
| September 30, 2020 | 45.29M |
| June 30, 2020 | 41.52M |
| March 31, 2020 | 41.48M |
| December 31, 2019 | 38.33M |
| September 30, 2019 | 36.29M |
| June 30, 2019 | 36.46M |
| March 31, 2019 | 34.85M |
| December 31, 2018 | 33.25M |
| September 30, 2018 | 28.81M |
| June 30, 2018 | 29.26M |
| March 31, 2018 | 23.55M |
| December 31, 2017 | 19.38M |
| Date | Value |
|---|---|
| September 30, 2017 | 18.42M |
| June 30, 2017 | 14.98M |
| March 31, 2017 | 12.94M |
| December 31, 2016 | 13.89M |
| September 30, 2016 | 17.01M |
| June 30, 2016 | 19.45M |
| March 31, 2016 | 15.27M |
| December 31, 2015 | 19.91M |
| September 30, 2015 | 16.69M |
| June 30, 2015 | 15.62M |
| March 31, 2015 | 14.98M |
| December 31, 2014 | 15.09M |
| September 30, 2014 | 16.34M |
| June 30, 2014 | 13.46M |
| March 31, 2014 | 12.08M |
| December 31, 2013 | 10.84M |
| September 30, 2013 | 8.703M |
| June 30, 2013 | 9.278M |
| March 31, 2013 | 8.22M |
| December 31, 2012 | 9.282M |
| September 30, 2012 | 7.57M |
| June 30, 2012 | 7.574M |
| March 31, 2012 | 7.283M |
| December 31, 2011 | 7.878M |
| September 30, 2011 | 7.839M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
36.29M
Minimum
Sep 2019
66.18M
Maximum
Dec 2022
52.97M
Average
56.43M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 3.20M |
| Perspective Therapeutics Inc | 6.08M |
| Protalix BioTherapeutics Inc | 3.102M |
| Electromed Inc | 0.107M |
| Armata Pharmaceuticals Inc | 7.928M |